Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.
Pulido I, Ollosi S, Aparisi S, Becker JH, Aliena-Valero A, Benet M, Rodríguez ML, López A, Tamayo-Torres E, Chuliá-Peris L, García-Cañaveras JC, Soucheray M, Dalheim AV, Salom JB, Qiu W, Kaja S, Fernández-Coronado JA, Alandes S, Alcácer J, Al-Shahrour F, Borgia JA, Juan O, Nishimura MI, Lahoz A, Carretero J, Shimamura T. Pulido I, et al. Among authors: carretero j. Cancer Res. 2020 Oct 1;80(19):4224-4232. doi: 10.1158/0008-5472.CAN-20-0141. Epub 2020 Aug 3. Cancer Res. 2020. PMID: 32747363 Free PMC article.
Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK. Shimamura T, et al. Among authors: carretero j. Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17. Clin Cancer Res. 2013. PMID: 24045185 Free PMC article.
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour F, Carretero J, Wong KK, Jänne PA, Shapiro GI, Shimamura T. Soucheray M, et al. Among authors: carretero j. Cancer Res. 2015 Oct 15;75(20):4372-83. doi: 10.1158/0008-5472.CAN-15-0377. Epub 2015 Aug 17. Cancer Res. 2015. PMID: 26282169 Free PMC article.
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.
Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodríguez ML, Gandhi R, Lafuente-Sanchis A, Aupí M, Alcácer Fernández-Coronado J, Martín-Martorell P, Cremades A, Galbis-Caravajal JM, Alcácer J, Christensen CL, Simms P, Hess A, Asahina H, Kahle MP, Al-Shahrour F, Borgia JA, Lahoz A, Insa A, Juan O, Jänne PA, Wong KK, Carretero J, Shimamura T. Becker JH, et al. Among authors: carretero j. Cancer Res. 2019 Sep 1;79(17):4439-4452. doi: 10.1158/0008-5472.CAN-19-0024. Epub 2019 Jul 4. Cancer Res. 2019. PMID: 31273063 Free PMC article.
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.
Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KK. Christensen CL, et al. Among authors: carretero j. Cancer Cell. 2014 Dec 8;26(6):909-922. doi: 10.1016/j.ccell.2014.10.019. Cancer Cell. 2014. PMID: 25490451 Free PMC article.
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI. Shimamura T, et al. Among authors: carretero j. Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17. Clin Cancer Res. 2012. PMID: 22806877 Free PMC article.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK. Akbay EA, et al. Among authors: carretero j. Cancer Discov. 2013 Dec;3(12):1355-63. doi: 10.1158/2159-8290.CD-13-0310. Epub 2013 Sep 27. Cancer Discov. 2013. PMID: 24078774 Free PMC article.
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Weaver Z, Difilippantonio S, Carretero J, Martin PL, El Meskini R, Iacovelli AJ, Gumprecht M, Kulaga A, Guerin T, Schlomer J, Baran M, Kozlov S, McCann T, Mena S, Al-Shahrour F, Alexander D, Wong KK, Van Dyke T. Weaver Z, et al. Among authors: carretero j. Cancer Res. 2012 Nov 15;72(22):5921-33. doi: 10.1158/0008-5472.CAN-12-0736. Epub 2012 Sep 11. Cancer Res. 2012. PMID: 22969147 Free PMC article.
β-catenin contributes to lung tumor development induced by EGFR mutations.
Nakayama S, Sng N, Carretero J, Welner R, Hayashi Y, Yamamoto M, Tan AJ, Yamaguchi N, Yasuda H, Li D, Soejima K, Soo RA, Costa DB, Wong KK, Kobayashi SS. Nakayama S, et al. Among authors: carretero j. Cancer Res. 2014 Oct 15;74(20):5891-902. doi: 10.1158/0008-5472.CAN-14-0184. Epub 2014 Aug 27. Cancer Res. 2014. PMID: 25164010 Free PMC article.
398 results